Guoqing Qian1, Zhongliang Hu1,2, Hong Xu3, Susan Müller4, Dongsheng Wang1, Hongzheng Zhang1, Sungjin Kim5, Zhengjia Chen5, Nabil F Saba1, Dong M Shin1, Andrew Y Wang3, Zhuo Georgia Chen1. 1. Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA. 2. Department of Pathology, Xiangya Hospital, Xiangya Medical School, Central South University, Changsha, Hunan, China. 3. Ocean NanoTech, San Diego, CA, USA. 4. Department of Otolaryngology, Emory University School of Medicine, Atlanta, GA, USA. 5. Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, USA.
Abstract
BACKGROUND: p16 overexpression is a highly sensitive yet moderately specific biomarker for predicting human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC). Nuclear β-catenin translocation has been linked to HPV-positive OPSCC. However, whether the strategy of combining β-catenin with p16 can better predict HPV-associated OPSCC remains unknown. METHODS: We evaluated the expression of p16 and β-catenin (nuclear and membrane) by immunohistochemistry staining in 101 OPSCC tissues and HPV status by HPV DNA in situ hybridization. Logistic regression models were used to evaluate single or multiple biomarkers for HPV prediction. The prediction power, sensitivity, and specificity were determined by receiver operating characteristic (ROC) analyses. RESULTS: Our data showed that upon univariate analysis, p16 and nuclear β-catenin were positively correlated with HPV status, while membrane β-catenin was inversely correlated with HPV status (P < 0.01). p16 showed the highest HPV predictive power, with area under the curve (AUC) of 0.9074 compared to 0.6762 for nuclear β-catenin and 0.7635 for membrane β-catenin, respectively, indicating differential accuracies for HPV prediction. Multivariable analysis showed that p16 was significantly correlated with HPV, while nuclear and membrane β-catenin showed marginal significance. The three-biomarker model was similarly sensitive (98.9% vs. 100%) but more specific (88.9% vs. 81%) than p16 alone, which also showed a good predictive value for overall (P = 0.0002) survival and disease-free (P = 0.0158) survival. CONCLUSION: Our study suggests a novel model of combining p16 and subcellular β-catenin for prediction of HPV-associatred OPSCC, and this finding deserves further validation.
BACKGROUND:p16 overexpression is a highly sensitive yet moderately specific biomarker for predicting human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC). Nuclear β-catenin translocation has been linked to HPV-positive OPSCC. However, whether the strategy of combining β-catenin with p16 can better predict HPV-associated OPSCC remains unknown. METHODS: We evaluated the expression of p16 and β-catenin (nuclear and membrane) by immunohistochemistry staining in 101 OPSCC tissues and HPV status by HPV DNA in situ hybridization. Logistic regression models were used to evaluate single or multiple biomarkers for HPV prediction. The prediction power, sensitivity, and specificity were determined by receiver operating characteristic (ROC) analyses. RESULTS: Our data showed that upon univariate analysis, p16 and nuclear β-catenin were positively correlated with HPV status, while membrane β-catenin was inversely correlated with HPV status (P < 0.01). p16 showed the highest HPV predictive power, with area under the curve (AUC) of 0.9074 compared to 0.6762 for nuclear β-catenin and 0.7635 for membrane β-catenin, respectively, indicating differential accuracies for HPV prediction. Multivariable analysis showed that p16 was significantly correlated with HPV, while nuclear and membrane β-catenin showed marginal significance. The three-biomarker model was similarly sensitive (98.9% vs. 100%) but more specific (88.9% vs. 81%) than p16 alone, which also showed a good predictive value for overall (P = 0.0002) survival and disease-free (P = 0.0158) survival. CONCLUSION: Our study suggests a novel model of combining p16 and subcellular β-catenin for prediction of HPV-associatred OPSCC, and this finding deserves further validation.
Authors: Brian O'Sullivan; Shao Hui Huang; Lillian L Siu; John Waldron; Helen Zhao; Bayardo Perez-Ordonez; Ilan Weinreb; John Kim; Jolie Ringash; Andrew Bayley; Laura A Dawson; Andrew Hope; John Cho; Jonathan Irish; Ralph Gilbert; Patrick Gullane; Angela Hui; Fei-Fei Liu; Eric Chen; Wei Xu Journal: J Clin Oncol Date: 2013-01-07 Impact factor: 44.544
Authors: Andrew G Schache; Triantafilos Liloglou; Janet M Risk; Anastasia Filia; Terence M Jones; Jon Sheard; Julia A Woolgar; Timothy R Helliwell; Asterios Triantafyllou; Max Robinson; Philip Sloan; Colin Harvey-Woodworth; Daniel Sisson; Richard J Shaw Journal: Clin Cancer Res Date: 2011-10-01 Impact factor: 12.531
Authors: Beth Wadsworth; Jeffery M Bumpous; Alvin W Martin; Michael R Nowacki; Alfred B Jenson; Hanan Farghaly Journal: Head Neck Pathol Date: 2011-07-30
Authors: Haïtham Mirghani; Furrat Amen; Frederique Moreau; Joel Guigay; Malek Ferchiou; Antoine E Melkane; Dana M Hartl; Jean Lacau St Guily Journal: Oral Oncol Date: 2013-10-26 Impact factor: 5.337
Authors: Peter K C Goon; Margaret A Stanley; Jörg Ebmeyer; Lars Steinsträsser; Tahwinder Upile; Waseem Jerjes; Manuel Bernal-Sprekelsen; Martin Görner; Holger H Sudhoff Journal: Head Neck Oncol Date: 2009-10-14